Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma.

Stewart JP, Thompson A, Santra M, Barlogie B, Lappin TR, Shaughnessy J Jr.

Br J Haematol. 2004 Jul;126(1):72-6.

PMID:
15198734
2.

Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.

Hudlebusch HR, Theilgaard-Mönch K, Lodahl M, Johnsen HE, Rasmussen T.

Br J Haematol. 2005 Sep;130(5):700-8.

PMID:
16115125
3.

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.

Santra M, Zhan F, Tian E, Barlogie B, Shaughnessy J Jr.

Blood. 2003 Mar 15;101(6):2374-6. Epub 2002 Nov 14.

4.

Characterization of oncogene dysregulation in multiple myeloma by combined FISH and DNA microarray analyses.

Fabris S, Agnelli L, Mattioli M, Baldini L, Ronchetti D, Morabito F, Verdelli D, Nobili L, Intini D, Callea V, Stelitano C, Lombardi L, Neri A.

Genes Chromosomes Cancer. 2005 Feb;42(2):117-27.

PMID:
15543617
5.

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.

Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, Mant MJ, Belch AR, Pilarski LM.

Blood. 2003 Feb 15;101(4):1520-9. Epub 2002 Oct 3.

6.

The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.

Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, Bergsagel PL.

Blood. 1998 Nov 1;92(9):3025-34.

7.

Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.

Chandesris MO, Soulier J, Labaume S, Crinquette A, Repellini L, Chemin K, Malphettes M, Fieschi C, Asli B, Uzunhan Y, Fermand JP, Bories JC, Arnulf B.

Br J Haematol. 2007 Feb;136(4):609-14.

PMID:
17223917
8.

A molecular study of the t(4;14) in multiple myeloma.

Sibley K, Fenton JA, Dring AM, Ashcroft AJ, Rawstron AC, Morgan GJ.

Br J Haematol. 2002 Aug;118(2):514-20.

PMID:
12139740
9.

Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.

Malgeri U, Baldini L, Perfetti V, Fabris S, Vignarelli MC, Colombo G, Lotti V, Compasso S, Bogni S, Lombardi L, Maiolo AT, Neri A.

Cancer Res. 2000 Aug 1;60(15):4058-61.

10.

MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells.

Brito JL, Walker B, Jenner M, Dickens NJ, Brown NJ, Ross FM, Avramidou A, Irving JA, Gonzalez D, Davies FE, Morgan GJ.

Haematologica. 2009 Jan;94(1):78-86. doi: 10.3324/haematol.13426. Epub 2008 Dec 4.

11.

Transcription repression activity is associated with the type I isoform of the MMSET gene involved in t(4;14) in multiple myeloma.

Todoerti K, Ronchetti D, Agnelli L, Castellani S, Marelli S, Deliliers GL, Zanella A, Lombardi L, Neri A.

Br J Haematol. 2005 Oct;131(2):214-8.

PMID:
16197452
12.

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.

Keats JJ, Maxwell CA, Taylor BJ, Hendzel MJ, Chesi M, Bergsagel PL, Larratt LM, Mant MJ, Reiman T, Belch AR, Pilarski LM.

Blood. 2005 May 15;105(10):4060-9. Epub 2005 Jan 27.

13.

Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.

Perfetti V, Coluccia AM, Intini D, Malgeri U, Vignarelli MC, Casarini S, Merlini G, Neri A.

Am J Pathol. 2001 May;158(5):1599-603.

14.

Expression of fibroblast growth factor and FGF-receptor family genes in human myeloma cells, including lines possessing t(4;14)(q16.3;q32. 3) and FGFR3 translocation.

Otsuki T, Yamada O, Yata K, Sakaguchi H, Kurebayashi J, Nakazawa N, Taniwaki M, Yawata Y, Ueki A.

Int J Oncol. 1999 Dec;15(6):1205-12.

PMID:
10568829
15.

A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.

Dring AM, Davies FE, Fenton JA, Roddam PL, Scott K, Gonzalez D, Rollinson S, Rawstron AC, Rees-Unwin KS, Li C, Munshi NC, Anderson KC, Morgan GJ.

Clin Cancer Res. 2004 Sep 1;10(17):5692-701.

16.

[Detection of IgH-MMSET fusion gene in multiple myeloma patients and its significance].

Jiang H, Hou J, Chen YB, Ding SQ.

Zhonghua Xue Ye Xue Za Zhi. 2003 Oct;24(10):515-8. Chinese.

PMID:
14690579
17.

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14).

Intini D, Baldini L, Fabris S, Lombardi L, Ciceri G, Maiolo AT, Neri A.

Br J Haematol. 2001 Aug;114(2):362-4.

PMID:
11529856
19.

Cyclin D3 at 6p21 is dysregulated by recurrent chromosomal translocations to immunoglobulin loci in multiple myeloma.

Shaughnessy J Jr, Gabrea A, Qi Y, Brents L, Zhan F, Tian E, Sawyer J, Barlogie B, Bergsagel PL, Kuehl M.

Blood. 2001 Jul 1;98(1):217-23.

20.

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

Keats JJ, Reiman T, Belch AR, Pilarski LM.

Leuk Lymphoma. 2006 Nov;47(11):2289-300. Review.

PMID:
17107900

Supplemental Content

Support Center